The general public doesn’t realize the magnitude of problems faced by children and adolescents with cancer and those who survive their cancers. The Awareness Interest Group seeks to shine the spotlight on facts, such as:
- Childhood cancer is the leading cause of death by disease among children and adolescents in the United States.
- Most causes of childhood cancer are unknown and not preventable.
- The incidence of childhood cancer is on the increase.
- Most survivors will experience significant debilitating complications that result from their treatment regimes.
- Children and adolescents who have or have had cancer are much more likely (more than 60%) to face bullying than their healthy classmates.
- Only four drugs have been developed and approved to treat a pediatric cancer in the last quarter century.
CAC2 member organizations with an interest in Awareness are encouraged to participate in the work of the CAC2 Advocacy and Awareness Interest Group. Notes from the 2019 meeting of the working group are available here. Email if you would like more information on how to be involved with CAC2 awareness initiatives.
Raising awareness is crucial to increasing research funds and legislative efficacy.
Collaborating amplifies our impact.
Latest CAC2 and Community News
CAC2 Childhood Cancer Community News Digest (March 13-19)
Assorted News from the Last Week: Results from a new study show that giving a drug called dexrazoxane (Zinecard) before each dose of doxorubicin substantially decreases the risk that childhood cancer survivors will have treatment-related heart problems in adulthood. Keeping ...
CAC2 Childhood Cancer Community News Digest (March 6-12)
Assorted News from the Last Week: This year's Grand Challenge includes a focus on pediatric solid tumors! One of the nine announced challenges seeks to identify new therapies that target drivers of solid tumors in children, to improve survival and ...
CAC2 Childhood Cancer Community News Digest (February 27-March 5)
Assorted News from the Last Week: In March last year, the CCDI Molecular Characterization Initiative (MCI) launched. Since then, it has opened enrollment to children, adolescents, and young adults newly diagnosed with central nervous system tumors, soft tissue sarcomas, and ...